# Is PT-141 FDA-Approved? Regulatory Status of Bremelanotide

> Is PT-141 FDA-approved? Yes for one use: bremelanotide was approved in 2019 for HSDD in premenopausal women. Every other use is off-label. The regulatory status, explained.

Approved for one use, off-label for the rest, and unregulated as a 'research chemical' — the distinctions that matter, plainly.

## Start here

The honest answer to **is PT-141 fda-approved** is: yes, but only for one narrow use. On June 21, 2019, the FDA approved bremelanotide (the drug name for PT-141) as an injection for one condition — acquired, generalized HSDD (low sexual desire that causes distress) in premenopausal women [7].

That is the whole of the approval. It is not approved for men, not for postmenopausal women, and not to enhance "performance" or for weight [7]. Those other uses are off-label (a doctor may legally prescribe an approved drug for an unapproved use, but the FDA has not vetted it for that purpose) or purely experimental. And there is a third, important category: "PT-141" sold as a research chemical sits entirely outside the pharmacy system, with no oversight at all [7]. Below, each of these is spelled out.

## The one approved use

Bremelanotide was approved under NDA 210557 on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [7]. "Acquired" means the low desire developed after a period of normal desire; "generalized" means it is not tied to a specific partner or situation.

The approval rested on the two RECONNECT trials (1,267 women), which showed bremelanotide improved desire and reduced desire-related distress versus placebo [3], plus a 52-week extension confirming durability and safety [4]. The labeled dose is 1.75 mg subcutaneously, as needed [7]. This is the only context in which PT-141 is an approved medicine.

## What is off-label or experimental

Everything beyond premenopausal HSDD is unapproved. Use in **men** is off-label and investigational — despite early erectile-dysfunction studies showing dose-related activity, and reviews framing bremelanotide as an early centrally acting option for men, none of it led to approval [1][9][11]. Use in **postmenopausal women** is likewise not approved.

The **weight and appetite** effects are a striking example. Because MC4R also controls appetite, high-frequency Phase 1 research dosing in obese women reduced body weight and caloric intake [8] — a genuine pharmacological effect, but an unapproved use studied at doses far above the approved one. Treat any non-HSDD claim as off-label or experimental, never as endorsed by the approval.

## The 'research chemical' question

A crucial distinction: the FDA-approved bremelanotide injection and "PT-141" sold as a research chemical are not the same thing in practice. The approved product is a regulated pharmaceutical with verified identity, purity, and dose. PT-141 marketed as a research chemical exists outside that framework, with no regulatory oversight of what is actually in the vial — identity, purity, or concentration [7].

That gap is why the research-grade peptide cannot be assumed to match the studied drug. The published evidence on this site describes the regulated drug and the laboratory research; it does not validate any unregulated product. As for sport: melanocortin agonists without current therapeutic approval in a context fall under the World Anti-Doping Agency's non-approved-substances category (S0), so athletes should consult current WADA guidance directly [7].

## Why the distinction matters

Keeping these categories straight is the single most useful thing a reader can do with PT-141. "FDA-approved" is true — but only for premenopausal HSDD, at one dose, as a regulated injection [7]. The same molecule used in men, after menopause, for performance, for weight, or bought as a research chemical is in a different regulatory world, and the safety data that supports the approval does not automatically carry over [7].

This site reads the research and the label so those lines stay visible. It is editorial, not medical advice, and it recommends no dose for anyone — decisions about an approved prescription belong with a licensed clinician [7].

---

A plain-English research desk for PT-141 (bremelanotide), reading the newest studies first — the one approved use named, the off-label uses flagged, the modest benefit and the nausea both kept in view; a reading desk, not a clinic, with nothing here dosed or sold.